Welcome to BioSeeker Group!

Triple Analysis: Colorectal Cancer, Angiogenesis and Peptides

Additional Information

Published Date Jan 7, 2013
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 3773
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Colorectal Cancer, Angiogenesis and Peptides in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Colorectal Cancer), one mechanism/target/effect area (Angiogenesis) and one compound specific area (Peptides).

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Colorectal Cancer, Angiogenesis and Peptides.

    To find out more about Triple Analysis: Colorectal Cancer, Angiogenesis and Peptides, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Colorectal Cancer, Angiogenesis and Peptides is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Colorectal Cancer), one mechanism/target/effect area (Angiogenesis) and one compound specific area (Peptides). Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Colorectal Cancer
The colorectal cancer report part comprises defined and up to date development strategies for 347 colorectal cancer drugs within the portfolio of 182 investigators, from Ceased to Marketed. This part extensively analyses their 210 identified drug targets, organized into 205 drug target strategies, and assesses them in eight different compound strategies in colorectal cancer.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Colorectal Cancer Pipeline: From Research and Development to Market

Part II: Angiogenesis
The angiogenesis affecting cancer drug report part comprises defined and up to date development strategies for 252 drugs in oncology within the portfolio of 151 companies world-wide, from Ceased to Marketed. The report extensively analyses their 177 identified drug targets, organized into 170 drug target strategies, and assesses them in 70 cancer indications.
This part is based on the following publication:
Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

Part III: Peptides
The peptide drug report part comprises defined and up to date development strategies for 171 drugs in oncology within the portfolio of 114 companies world-wide, from Ceased to Marketed. The report extensively analyses their 132 identified drug targets, organized into 109 drug target strategies, and assesses them in 62 cancer indications.
This part is based on the following publication:
Cancer Peptides: From First-in-Class to Best-in-Class?

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Colorectal Cancer
5.1 The Scope of this Report 28
6 Consider the Therapeutic Target Among Colorectal Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (210 Drug Targets) 32-451
7 Emerging New Products to Established Ones: Drug Target Strategies of Colorectal Cancer Drugs by their Highest Stage of Development (205 Drug Target Strategies and 347 Colorectal Cancer Drugs) 452-699
8 Compound Strategies at Work: Competitive Benchmarking of Colorectal Cancer Drugs by Compound Strategy (8 Compound Strategies) 700-745
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Colorectal Cancer Drug Pipeline by Investigator (182 Companies) 746-1,039
10 Disclaimer 1040
11 Drug Index 1041
12 Company Index 1050
Figures: Includes 6 Figures
Tables: Includes 242 Tables
Total Number of Pages: 1,056

Part II: Angiogenesis
5.1 The Scope of this Report 37
6 Consider the Therapeutic Target Among Angiogenesis Affecting Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (177 Drug Targets) 41-421
7 Emerging New Products to Established Ones: Drug Target Strategies of Angiogenesis Affecting Drugs in Oncology by their Highest Stage of Development (170 Drug Target Strategies and 252 Drugs) 424-666
8 Compound Strategies at Work: Competitive Benchmarking of Angiogenesis Affecting Cancer Drugs by Compound Strategy (7 Compound Strategies) 667-709
9 Selecting Indication for Angiogenesis Affecting Drugs in Oncology (70 Cancer Indications) 710-848
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Angiogenesis Affecting Drug Pipeline in Oncology by Investigator (151 Investigators and 252 Drugs) 849-1685
12 Drug Index 1687
13 Company Index 1697
Figures: Includes 7 Figures
Tables: Includes 310 Tables
Total Number of Pages: 1,704

Part III: Peptides
5.1 The Scope of this Report 27
6 Consider the Therapeutic Target Among Peptide Drugs in Cancer for the Highest Therapeutic Outcome and Return on Investment (132 Drug Targets) 31-252
7 First-in-Class and Me-too Analysis of Peptide Drugs in Cancer (109 Drug Target Strategies and 171 Drugs) 253-267
8 Is First-in-Class the Best-in-Class? (109 Drug Target Strategies and 171 Drugs) 268-387
9 The Competition through Close Mechanistic Approximation of Peptide Drugs in Cancer 388
10 Selecting Indication for Peptide Drugs in Oncology ( 62 Cancer Indications) 391-475
11 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Peptide Drug Pipeline by Investigator (114 Investigators and 171 Drugs) 476-1001
12 Disclaimer 1002
Figures: Includes 5 Figures
Tables: Includes 232 Tables
Total Number of Pages: 1,013

This Report Includes the Following Companies:
7TM Pharma
Abbott
Acceleron Pharma
Access
Active Biotech
Adherex
Advantagene
Advaxis
Advenchen
AEterna Zentaris
Affimed Therapeutics
Affymax
Agennix
Agenus
Aida Pharmaceuticals
Aileron Therapeutics
Alchemia
Alethia Biotherapeutics
Allos Therapeutics
Allostera
Allosterix
Alnylam
AlphaVax
Alseres Pharmaceuticals
Ambit Biosciences
Ambrilia Biopharma
Amgen
Amphora
Anavex Life Sciences
Anchor Therapeutics
AngioChem
Angiogen
Angiogenex
Angstrom Pharmaceuticals
Ansaris
Antisense Pharma
Antisoma
AplaGen Biopharmaceuticals
ApopLogic Pharmaceuticals
Apotex
Arana Therapeutics
Ardana
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Astellas
Astex Therapeutics
AstraZeneca
Attenuon
Austrianova
AVEO
AVI BioPharma
Baxter International
Bayer
Betapharma
BioAlliance Pharma
BioAxone
Biocad
Biocompatibles
Biogen Idec
Biokine Therapeutics
BioNumerik
BioVex
Boehringer Ingelheim
Bolder BioTechnology
Bristol-Myers Squibb
BTG
Camurus
Can-Fite BioPharma
CanBas
Cancer Advances
Cancer Innovations
Cancer Research Technology
CDG Therapeutics
Celator Pharmaceuticals
Celecure
Celera
Celgene
Cell Therapeutics
CellCeutix
Celldex Therapeutics
Cellmid
Celsion
Celtic Pharma
Center of Molecular Immunology
Cephalon
CG Therapeutics
ChemGenex Pharmaceuticals
ChemoCentryx
Chemokine Therapeutics
Chiasma
China Sky One Medical
Choongwae
Circadian Technologies
Clavis Pharma
Cleveland BioLabs
Clinuvel
Compugen
Cosmo Pharmaceuticals
Cue Biotech
CuraGen
Curaxis
CureTech
Curis
Cyclacel
Cylene Pharmaceuticals
Cynvec
CytImmune Sciences
Cytochroma
Cytokinetics
Daiichi Sankyo
Dainippon Sumitomo Pharma
Debiopharm
Deciphera Pharmaceuticals
Dendreon
Digna Biotech
Dongkook Pharm
Dyax
Dynavax Technologies
EGEN Inc
Eisai
Eli Lilly
Endo Pharmaceuticals
Enkam Pharmaceuticals
EntreMed
Enzon
Epeius Biotechnologies
EpiCept
Esperance Pharmaceuticals
Etubics
Exelixis
ExonHit Therapeutics
FasTrack Pharmaceuticals
Five Prime Therapeutics
Formula Pharmaceuticals
Galena Biopharma
GammaCan
Generex
Genmab
GENova Biotherapeutics
Genovax
Genta
GenVec
Genzyme
Gilead Sciences
GlaxoSmithKline
Glide Pharma
Gliknik
GlycoGenesys
GP Pharm
Gradalis
Green Cross
Gryphon Therapeutics
Heidelberg Pharma
Hoffmann-La Roche
Human Genome Sciences
Hy BioPharma
Idera Pharmaceuticals
IkerChem
ImClone Systems
ImmunoCellular Therapeutics
Immunocore
ImmunoGen
Immunomedics
Immunotope
ImmuPharma
Incyte Corporation
InNexus Biotechnology
Innovive
Inovio
Insys Therapeutics
Introgen Therapeutics
Ipsen
ISA Pharmaceuticals
Isis Pharmaceuticals
Ivy Medical Chemicals
Jennerex Biotherapeutics
Johnson & Johnson
KAEL-GemVax
KAI Pharmaceuticals
Karus Therapeutics
Karyon-CTT
Kiadis
Kirax
Kirin Pharma
Kringle Pharma
Kyowa Hakko Kirin
Labopharm
Lee’s Pharmaceutical
Leo
Lorus Therapeutics
MacroGenics
Marillion Pharmaceuticals
MAT Biopharma
MBiotec
Meda
MediGene
Mediolanum
Merck & Co
Merck KGaA
Merrimack
Mersana Therapeutics
MethylGene
Micromet
Mitsubishi Tanabe Pharma
MolMed
Mologen
Morvus Technology
Nektar Therapeutics
Nemod Biotherapeutics
Nerviano Medical Sciences
Neurobiological Technologies
NewSouth Innovations
NicOx
Nidus Laboratories
Nippon Kayaku
Non-industrial source
Novartis
Novelix
Noxxon
NPS Pharmaceuticals
Nycomed Pharma
Oasmia
OncoGenex Pharmaceuticals
OncoMed
Onconova
OncoTherapy Science
Oncothyreon
Oncozyme Pharma
Onyvax
Orca Therapeutics
Orchestra Therapeutics
OSI Pharmaceuticals
Oxford BioMedica
OXiGENE
PanaGin
Pepscan Therapeutics
Peptagen
PepTx
Peregrine Pharmaceuticals
Pfizer
Pharmaclon
Pharmacopeia
PharmaGap
PharmaMar
Pharmexa
Pharminox
Philogen
PhiloGene
Pierre Fabre
Plexxikon
POZEN
Pro-Pharmaceuticals
Progen
Protagonist
Protein Sciences
Protgen
Protherics
PTC Therapeutics
Q Chip
QLT
Raptor Pharmaceutical
Receptor BioLogix
Regeneron
Rexahn
Rigel
Sanofi
Sanofi-Aventis
Santaris Pharma
Sarepta Therapeutics
Sareum
Scancell
SciClone Pharmaceuticals
Semafore Pharmaceuticals
Serometrix
Shionogi
Shire
Sigma-Tau
Simcere Pharmaceuticals
Soligenix
Spear Therapeutics
Spectrum Pharmaceuticals
Spirogen
SRI International
Stainwei Biotech
SuperGen
Supratek Pharma
Switch Pharma
SynDevRx
Synta Pharmaceuticals
Tactic Pharma
Taiho
Takeda
Talon Therapeutics
Targepeutics
Tau Therapeutics
Taxolog
Telik
Thallion Pharmaceuticals
The Genetics Company
Therion Biologics
Theryte
ThromboGenics
Tigris Pharmaceuticals
Titan Pharmaceuticals
ToolGen
TopoTarget
Tracon Pharmaceuticals
Transgene
Trion Pharma
UCB
Unigene
United Biomedical
Vaxil BioTherapeutics
Vaxon Biotech
VBL Therapeutics
Vertex Pharmaceuticals
Vical
Wilex
VioQuest Pharmaceuticals
Viralytics
Wyeth
Xerion
Xigen
Yakult Honsha
YM BioSciences
Zelos Therapeutics
Zensun
A Shortlist of Drugs Included are:
A6
abarelix
ABT-510
AEZS-108
afamelanotide
aflibercept
AMG-386
angiopep+paclitaxel
Angiozyme
apatinib
ARQ-197
atrasentan
axitinib
bevacizumab
BIBF-1120
BMS-690514
brivanib alaninate
capecitabine
catumaxomab
CBP-501
cediranib
cetuximab
cilengitide
corticorelin acetate
deslorelin
DI-17E6
dovitinib lactate
doxifluridine
E-75
E-7820
emepepimut-S
endostatin
ENMD-2076
enzastaurin hydrochloride
EP-100
everolimus
Exherin
foretinib
fosbretabulin tromethamine
FPI-01
GliaAtak
goserelin
GT-111
GV-1001
GX-301
HBP-347
Her-2/Neu peptides
histrelin
icrucumab
imMucin
interferon gamma
intetumumab
IPP-204106
irinotecan bead
irinotecan hydrochloride
ISA-P53-01
JI-101
kahalalide F
lanreotide
lenvatinib
leukemia vaccine
leuprolide
leuprolide acetate
leuprorelin
linifanib
LY-2275796
MDX-1379
MGCD-265
MGN-1703
midostaurin
motesanib diphosphate
muparfostat (IV)
NAFB001
netupitant
NGR-TNF
octreotide
octreotide, LAR
ON-01910
OTS-102
ozarelix
paclitaxel
PancAtak
panitumumab
pasireotide
pasireotide LAR
pazopanib hydrochloride
PCI-27483
pegdinetanib
perifosine
PF-4856884
plitidepsin
polyclonal antibody stimulator
ponatinib
ProstAtak
PTC-299
RAF-265
raltitrexed
ramucirumab
regorafenib
ridaforolimus
rindopepimut
romurtide
sirolimus
sorafenib tosylate
sotatercept
SU-6668
sunitinib malate
Survivac
talactoferrin alfa
TAS-102
tasquinimod
TB-403
tegafur + uracil
tegafur + uracil + leucovorin
telatinib
Tenarad
thymalfasin
tipifarnib
tivozanib
TM-30339
TRC-105
TS-1
vandetanib
vapreotide, immediate-release
vismodegib
vitespen
volociximab
VX-001
XL-184
XL-647

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Colorectal Cancer, Angiogenesis and Peptides.
    To find out more about Triple Analysis: Colorectal Cancer, Angiogenesis and Peptides, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Colorectal Cancer, Angiogenesis and Peptides is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Breast Cancer, Angiogenesis and Peptides
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Breast Cancer), one mechanism/target/effect area (Angiogenesis) and one compound specific area (Peptides). Learn More


Triple Analysis: Prostate Cancer, Angiogenesis and Cancer Vaccines
This triple analysis focuses on cancer drug development strategies in Prostate Cancer and by the two mechanism/target/effect areas of Angiogenesis and Cancer Vaccines. Learn More

Other selected research from the 'Oncology' category:


Commercializing Peptides in Cancer: The Faster Route to Consider Your Options and Position of Others
This report will excel your competitive awareness and decrease your decision making time in managing peptide drug development in cancer. Learn More


The Commercial Success of Cancer Therapeutic Antibodies - The Formation of a Second Wave
The blockbuster drugs Rituxan, Avastin, and Erbitux have change the way the industry looks upon antibody treatment of cancer in the same way that Taxol changed the way pharmaceutical companies look at the possibilities in the field of cancer therapeutics. Learn More